MRKR
Marker TherapeuticsยทNASDAQ
--
--(--)
--
--(--)
MRKR Profile
Marker Therapeutics, Inc.
A clinical-stage immuno-oncology company that develops next-generation T cell-based immunotherapies for hematological malignancies and solid tumor indications
Biological Technology
--
11/08/2016
NASDAQ Stock Exchange
5
12-31
Common stock
2450 Holcombe Blvd, TMC Partners Office 1.311, Houston, Texas 77021
--
Marker Therapeutics, Inc., was originally incorporated under the laws of Nevada in 1991 and re-incorporated in Delaware in October 2018. The company is a clinical-stage immuno-oncology company developing novel T-cell immunotherapies using its multi-antigen recognition T-cell technology. Its method is designed to target a variety of tumor-associated antigens to treat hematological malignancies and solid tumors without the need for genetic modification.
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
